Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares. View CRBP analyst ratings or view top-rated stocks .

What is Corbus Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 12-month target prices for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $3.00 to $51.00. On average, they anticipate the company's share price to reach $27.00 in the next year. This suggests a possible upside of 21.9% from the stock's current price. View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts .

How have CRBP shares performed in 2024?

Corbus Pharmaceuticals' stock was trading at $6.04 at the start of the year. Since then, CRBP stock has increased by 266.7% and is now trading at $22.15. View the best growth stocks for 2024 here .

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our CRBP earnings forecast .

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.10. The biopharmaceutical company earned $0.10 million during the quarter, compared to analysts' expectations of $0.81 million.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V) , HP (HPQ) , Fortive (FTV) , Lowe's Companies (LOW) , Sorrento Therapeutics (SRNE) , Exelixis (EXEL) , Matinas BioPharma (MTNB) , Inovio Pharmaceuticals (INO) and KushCo (KSHB) .

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.38%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cormorant Asset Management, Lp, Craig Stuart Millian, Sean F Moran and Yuval Cohen . View institutional ownership trends .

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

$22.15

+0.52 (+2.40%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $21.18
▼
$22.73
50-Day Range: $5.25
▼
$29.49
52-Week Range: $2.11
▼
$39.96

Volume: 158,000 shs
Average Volume: 2.34 million shs
Market Capitalization: $214.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.00

Get Corbus Pharmaceuticals alerts:

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 21.9% Upside
$27.00 Price Target
Short Interest: Healthy
0.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: 0.94
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$23.36 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($11.00) to ($8.10) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.25 out of 5 stars

Medical Sector

143rd out of 922 stocks

Pharmaceutical Preparations Industry

54th out of 429 stocks

2.5

Analyst's Opinion

Consensus Rating
Corbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.00, Corbus Pharmaceuticals has a forecasted upside of 21.9% from its current price of $22.15.
Amount of Analyst Coverage
Corbus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.64% of the float of Corbus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Corbus Pharmaceuticals has recently decreased by 29.40%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Corbus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corbus Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Corbus Pharmaceuticals is -0.65.

3.3

News and Social Media Coverage

News Sentiment
Corbus Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Corbus Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
29 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 867% compared to the previous 30 days.
MarketBeat Follows
22 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corbus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,362,056.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Corbus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 16.73% of the stock of Corbus Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($11.00) to ($8.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corbus Pharmaceuticals is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corbus Pharmaceuticals is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corbus Pharmaceuticals has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRBP Stock News Headlines

February 5, 2024 | marketbeat.com

Corbus Pharmaceuticals stock: An explosive 342% YTD surge

Shares of CRBP have already experienced a meteoric rise of over 300% year-to-date, thanks to early but promising data from its Phase 1 trial.

February 7, 2024 | msn.com

Corbus Pharmaceuticals Announces Chief Scientific Officer Resignation

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

February 7, 2024 | americanbankingnews.com

Insider Buying: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Major Shareholder Buys 750,000 Shares of Stock

February 6, 2024 | finance.yahoo.com

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024 | msn.com

Corbus Pharmaceuticals Shares Updated Corporate Insights

February 3, 2024 | morningstar.com

Corbus Pharmaceuticals Holdings Inc

February 3, 2024 | americanbankingnews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Rating Increased to Hold at StockNews.com

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

February 2, 2024 | finance.yahoo.com

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

February 2, 2024 | msn.com

Corbus Pharmaceuticals Strikes Deal for Public Stock Offering

February 1, 2024 | benzinga.com

Corbus Pharmaceuticals Stock (NASDAQ:CRBP), Analyst Ratings, Price Targets, Predictions

February 1, 2024 | msn.com

What's Going On With Cancer-Focused Corbus Pharmaceuticals Stock Today?

February 1, 2024 | finance.yahoo.com

Retail investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) are its biggest bettors, and their bets paid off as stock gained 214% last week

January 31, 2024 | msn.com

$16.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying

January 31, 2024 | msn.com

Why Corbus Pharmaceuticals Shares Are Gaining Today

January 31, 2024 | markets.businessinsider.com

Corbus Pharmaceutical Prices Offering Of Approx. 4.3 Mln Shares At $19 Per Share; Stock Up

January 31, 2024 | finance.yahoo.com

Corbus Pharmaceuticals Announces Pricing of Public Offering

January 31, 2024 | markets.businessinsider.com

Corbus Pharma Announces Proposed Public Offering; Stock Surges

January 30, 2024 | investing.com

Corbus Pharmaceuticals Holding (CRBP)

January 30, 2024 | finance.yahoo.com

Corbus Pharmaceuticals Announces Proposed Public Offering

January 30, 2024 | msn.com

Corbus Pharmaceuticals Raises $16.8 Million from Stock Sale

January 29, 2024 | seekingalpha.com

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

January 29, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Corbus Pharmaceuticals (CRBP)

January 29, 2024 | seekingalpha.com

Corbus Pharma reverses gains on common stock offering

January 29, 2024 | finance.yahoo.com

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 28, 2024 | nasdaq.com

Corbus Pharma Spikes 256% On Positive Results For CRB-701 In First Human Study

See More Headlines

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 2/11/2024
Next Earnings (Estimated): 3/05/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CRBP
CUSIP: N/A
CIK: 1595097
Web: www.corbuspharma.com
Phone: (617) 963-0100
Fax: 617-663-6085
Employees: 33
Year Founded: 2009

Price Target and Rating

Average Stock Price Target: $27.00
High Stock Price Target: $51.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +21.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -320.24%
Return on Assets: -95.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.99
Quick Ratio: 0.99

Sales & Book Value

Annual Sales: $880,000.00
Price / Sales: 243.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.91 per share
Price / Book: 2.80

Miscellaneous

Outstanding Shares: 9,690,000
Free Float: 9,029,000
Market Cap: $214.63 million
Optionable: No Data
Beta: 2.41

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Yuval Cohen Ph.D. (Age 49)
CEO & Director
Comp: $890.67k
Mr. Sean F. Moran CPA (Age 66)
M.B.A., Chief Financial Officer
Comp: $579.05k
Dr. Rachael Brake Ph.D. (Age 52)
Chief Scientific Officer
Comp: $552.22k
Ted Jenkins
Senior Director of Investor Relations & Corporate Communications
Ms. Lindsey Smith
Head of Corporate Communications & Patient Advocacy
Ms. Christina Bertsch
Head of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRBP Stock Analysis - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings or view top-rated stocks.
What is Corbus Pharmaceuticals' stock price target for 2024?: 2 equities research analysts have issued 12-month target prices for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $3.00 to $51.00. On average, they anticipate the company's share price to reach $27.00 in the next year. This suggests a possible upside of 21.9% from the stock's current price.
View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts.
How have CRBP shares performed in 2024?: Corbus Pharmaceuticals' stock was trading at $6.04 at the start of the year. Since then, CRBP stock has increased by 266.7% and is now trading at $22.15.
View the best growth stocks for 2024 here.
When is Corbus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our CRBP earnings forecast.

How were Corbus Pharmaceuticals' earnings last quarter?: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.10. The biopharmaceutical company earned $0.10 million during the quarter, compared to analysts' expectations of $0.81 million.
What other stocks do shareholders of Corbus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).
Who are Corbus Pharmaceuticals' major shareholders?: Corbus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.38%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cormorant Asset Management, Lp, Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends.
How do I buy shares of Corbus Pharmaceuticals?: Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRBP) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial